Sittner & Nelson’s AbbVie ABBV Stock Holding History

Sittner & Nelson’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296K	Buy	1,178 +14	+1%	+$3.01K	0.09%	142
2026 Q1	$253K	Hold	1,164	–	–	0.09%	142
2025 Q4	$260K	Hold	1,164	–	–	0.09%	140
2025 Q3	$269K	Hold	1,164	–	–	0.1%	121
2025 Q2	$216K	Hold	1,164	–	–	0.09%	139
2025 Q1	$244K	Hold	1,164	–	–	0.1%	123
2024 Q4	$207K	Hold	1,164	–	–	0.09%	125
2024 Q3	$230K	Hold	1,164	–	–	0.1%	123
2024 Q2	$200K	Sell	1,164 -762	-40%	-$126K	0.1%	114
2024 Q1	$351K	Buy	1,926 +2	+0.1%	+$345	0.18%	84
2023 Q4	$298K	Buy	1,924 +50	+3%	+$7.29K	0.16%	90
2023 Q3	$279K	Sell	1,874 -25	-1%	-$3.67K	0.16%	88
2023 Q2	$256K	Sell	1,899 -475	-20%	-$69.7K	0.14%	94
2023 Q1	$378K	Hold	2,374	–	–	0.22%	79
2022 Q4	$384K	Hold	2,374	–	–	0.23%	79
2022 Q3	$319K	Sell	2,374 -148	-6%	-$21.2K	0.21%	81
2022 Q2	$386K	Buy	2,522 +606	+32%	+$92.6K	0.25%	71
2022 Q1	$311K	Hold	1,916	–	–	0.18%	83
2021 Q4	$259K	Buy	1,916 +1,260	+192%	+$149K	0.15%	91
2021 Q3	$71K	Hold	656	–	–	0.05%	158
2021 Q2	$74K	Hold	656	–	–	0.05%	146
2021 Q1	$71K	Buy	656 +42	+7%	+$4.49K	0.05%	147
2020 Q4	$66K	Buy	+614	New	+$59K	0.06%	142

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sittner & Nelson's ABBV Position: Q2 2026 in Review

Sittner & Nelson increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $3.01K and bringing the position to 1,178 shares worth $296K. The position accounts for 0.09% of the portfolio, ranked #142.

Sittner & Nelson first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. The position peaked at $386K in Q2 2022. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sittner & Nelson held 1,178 shares of AbbVie worth $296K as of Q2 2026.
Sittner & Nelson bought 14 AbbVie shares in Q2 2026, an estimated $3.01K.
AbbVie made up 0.09% of Sittner & Nelson's portfolio in Q2 2026, its #142 holding.
Sittner & Nelson first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
Sittner & Nelson's AbbVie position peaked at $386K in Q2 2022.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.